{"id":769,"date":"2026-10-19T21:12:38","date_gmt":"2026-10-20T01:12:38","guid":{"rendered":"http:\/\/novameds.local\/ca\/?post_type=product&#038;p=769"},"modified":"2026-10-19T21:58:15","modified_gmt":"2026-10-20T01:58:15","slug":"catalog-cibinitide-ara-290-16mg","status":"publish","type":"product","link":"https:\/\/novameds.health\/ca\/product\/catalog-cibinitide-ara-290-16mg\/","title":{"rendered":"Cibinitide ARA-290 16mg"},"content":{"rendered":"<section id=\"composition\" data-nav=\"Composition and product details\">\n<h2>Composition and product details<\/h2>\n<div class=\"nm-catalog-document\">\n<div>\n<h2>Overview<\/h2>\n<div>\n<p>Cibinitide (ARA-290) is a synthetic peptide engineered from a structural region of erythropoietin (EPO), designed to engage the innate repair receptor (IRR) \u2014 a heterodimeric receptor complex distinct from the classical homodimeric erythropoietin receptor responsible for erythropoiesis.<\/p>\n<p>Research interest centers on its capacity to activate IRR-mediated signalling without the haematopoietic effects associated with full EPO receptor engagement. Research applications include innate repair receptor pathway studies, cytoprotective signalling research, and EPO-derived peptide structure-activity investigation.<\/p>\n<ul>\n<li> <span><b>High Purity<\/b> \u2013 99% Purity Guaranteed<\/span><\/li>\n<li> Independently Lab Tested<\/li>\n<li> Research Grade Quality<\/li>\n<li> For Laboratory Research Use Only<\/li>\n<\/ul><\/div>\n<div>\n<p><a href=\"https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/91810664\" target=\"_blank\" rel=\"noopener noreferrer\">Molecular data on PubChem<\/a><\/p>\n<div>\n<div><span>Cibinitide ARA-290 16mg<\/span><span>1 vial | KIT (10 vials)<\/span><\/div>\n<\/div><\/div>\n<\/p><\/div>\n<div>\n<h2>Properties<\/h2>\n<div class=\"nm-catalog-table\" tabindex=\"0\" role=\"region\" aria-label=\"Product data\">\n<table>\n<tbody>\n<tr>\n<th>Chemical Formula<\/th>\n<td>C51H84N16O21<\/td>\n<\/tr>\n<tr>\n<th>Synonyms<\/th>\n<td>Cibinetide, PH-BSP, ARA290<\/td>\n<\/tr>\n<tr>\n<th>Molar Mass<\/th>\n<td>1257.31 g\/mol<\/td>\n<\/tr>\n<tr>\n<th>CAS Number<\/th>\n<td>1208243-50-8<\/td>\n<\/tr>\n<tr>\n<th>PubChem CID<\/th>\n<td>91810664<\/td>\n<\/tr>\n<tr>\n<th>Available formats<\/th>\n<td>1 vial \u00b7 KIT (10 vials)<\/td>\n<\/tr>\n<tr>\n<th>Shelf Life<\/th>\n<td>36 months<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div><\/div>\n<div>\n<h2>Research<\/h2>\n<p>\t\t\t\t\t<span>Cibinitide (ARA-290) was engineered from the helix-B surface region of erythropoietin to selectively engage the innate repair receptor, a complex formed by the EPO receptor and the common beta receptor subunit (CD131\/\u03b2cR), distinguishing its signalling profile from the homodimeric EPO receptor responsible for classical erythropoietic effects. Research models examine IRR-mediated activation of cytoprotective and anti-inflammatory intracellular signalling cascades, including studies of TRPV1 channel modulation and inflammatory pathway interactions, using cell-based receptor engagement assays and rodent models of tissue injury and inflammatory signalling. The structural basis for IRR-selective activity (rather than classical EPO receptor activation) is a central focus of structure-activity research within this peptide series. Independently third-party HPLC-tested; COA available per batch.<br \/>\n<\/span>\t\t\t\t\t<\/div>\n<div>\n<h2>Lab Results<\/h2>\n<p>Results refer to the tested sample. Check the batch and date in the report.<\/p>\n<div>\n<div>\n<div><\/div>\n<div>\n<div>Cibinitide ARA-290 (HPLC)<\/div>\n<div>March 4, 2025<\/div>\n<\/p><\/div>\n<div><a href=\"https:\/\/swisschems.is\/wp-content\/uploads\/2026\/06\/SC-HPLC-ARA290.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Open PDF<\/a><\/div>\n<\/p><\/div>\n<\/p><\/div>\n<\/p><\/div>\n<div>\n<h2>FAQ<\/h2>\n<div>\n<details>\n<summary>\n\t\t\t\t\t\t\t\t\t\t<span>How does cibinitide&#8217;s selectivity for the innate repair receptor distinguish it from native erythropoietin signaling?<\/span><\/p>\n<\/summary>\n<div>\n<p>Native erythropoietin activates the classical homodimeric EPO receptor to drive erythropoiesis (red blood cell production) in addition to other downstream effects.<\/p>\n<p>Cibinitide was engineered to selectively engage the innate repair receptor (IRR) \u2014 a distinct heterodimeric complex of the EPO receptor and the common beta receptor subunit (CD131) \u2014 without activating the homodimeric EPO receptor pathway responsible for erythropoietic effects.<\/p>\n<p>Research distinguishing these two signalling outcomes typically uses hematocrit or reticulocyte count as a readout for erythropoietic activity alongside IRR-specific signalling markers, to confirm selective IRR engagement without off-target erythropoietic stimulation.<\/p>\n<\/div>\n<\/details>\n<details>\n<summary>\n\t\t\t\t\t\t\t\t\t\t<span>What cell-based assays are used to study cibinitide&#8217;s activation of innate repair receptor signaling?<\/span><\/p>\n<\/summary>\n<div>\n<p>Cell lines expressing the IRR complex (EPO receptor plus CD131) are used in receptor engagement and downstream signalling assays, typically measuring activation of JAK2\/STAT5 or other cytoprotective signalling intermediates following cibinitide exposure, compared against cell lines expressing only the classical homodimeric EPO receptor to confirm receptor-complex-dependent selectivity. Inflammatory pathway readouts \u2014 such as NF-\u03baB activation status or downstream cytokine production \u2014 are also used in models examining cibinitide&#8217;s reported anti-inflammatory signalling effects.<\/p>\n<\/div>\n<\/details>\n<details>\n<summary>\n\t\t\t\t\t\t\t\t\t\t<span>What rodent injury models are used to study cibinitide&#8217;s cytoprotective signaling effects?<\/span><\/p>\n<\/summary>\n<div>\n<p>Rodent models of tissue injury and inflammatory challenge \u2014 including peripheral nerve injury, ischemia-reperfusion injury models, and inflammatory pain models \u2014 have been used to study cibinitide&#8217;s effects on cytoprotective and anti-inflammatory signalling pathways downstream of IRR activation. These studies typically combine behavioral or functional injury-recovery endpoints with tissue-level markers of inflammation and cell survival to characterise the peptide&#8217;s pathway-specific effects in an intact physiological system.<\/p>\n<\/div>\n<\/details><\/div>\n<\/p><\/div>\n<\/div>\n<\/section>\n","protected":false},"excerpt":{"rendered":"<p>Cibinitide (ARA-290) is a synthetic peptide engineered from a structural region of erythropoietin (EPO), designed to engage the innate repair receptor (IRR) \u2014 a heterodimeric receptor complex distinct from the classical homodimeric erythropoietin receptor responsible for erythropoiesis.<\/p>\n<p>Presentation: Cibinitide ARA-290 16mg.<\/p>\n<p>Select the required strength and pack size.<\/p>\n<p class=\"nm-research-disclaimer\">For laboratory research only. Not for human or veterinary use.<\/p>\n<p class=\"nm-catalog-image-note\"><small>Illustrative packaging generated with AI.<\/small><\/p>\n","protected":false},"featured_media":955,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[26],"product_tag":[],"nm_classification":[],"class_list":["post-769","product","type-product","status-publish","has-post-thumbnail","product_cat-recovery-regeneration","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"_links":{"self":[{"href":"https:\/\/novameds.health\/ca\/wp-json\/wp\/v2\/product\/769","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/novameds.health\/ca\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/novameds.health\/ca\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/novameds.health\/ca\/wp-json\/wp\/v2\/comments?post=769"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/novameds.health\/ca\/wp-json\/wp\/v2\/media\/955"}],"wp:attachment":[{"href":"https:\/\/novameds.health\/ca\/wp-json\/wp\/v2\/media?parent=769"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/novameds.health\/ca\/wp-json\/wp\/v2\/product_brand?post=769"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/novameds.health\/ca\/wp-json\/wp\/v2\/product_cat?post=769"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/novameds.health\/ca\/wp-json\/wp\/v2\/product_tag?post=769"},{"taxonomy":"nm_classification","embeddable":true,"href":"https:\/\/novameds.health\/ca\/wp-json\/wp\/v2\/nm_classification?post=769"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}